黑料吃瓜群网

Researchers from the , in association with European researchers, are investigating a range of FDA-approved drugs with the aim of helping kids with severe epilepsy.

Malignant migrating partial seizures in infancy (MMPSI) is a childhood epilepsy most commonly caused by mutations in the KCNT1 gene聽鈥� a gene responsible for regulating neuron activity in the central neural system. Children with this genetic condition are very unwell and can suffer up to 100 epileptic seizures a day.

There is no cure or current therapy to relieve the condition and the research aims to change this.

The researchers, funded by the Channel 7 Children鈥檚 Research Foundation, will investigate a range of drugs flagged as possible options for children with MMPSI, testing their effectiveness on reducing seizures.

Chief investigator Professor Leanne Dibbens (UniSA) is an expert in the genetics of childhood epilepsy and was involved in the first discovery of the genetic mutations that cause epilepsies, including MMPSI. She said that this research could deliver life-changing outcomes for affected children and their families.

鈥淭he non-seizure drug Quinidine has been trialled in a number of children, but with little improvement, so there鈥檚 an acute need for new drugs to treat children with KCNT1 mutations.

鈥淲e will be investigating a range of FDA-approved drugs that have been identified to limit the effects of the potassium gene mutation, and in this way, we hope to identify a high potential drug to treat this type of severe epilepsy,鈥� Dibbens said.

A significant advantage of the study is that the eight drugs within the study are already FDA-approved, which means the need for lengthy and costly clinical trials to prove the drugs鈥� safety and efficacy is eliminated.

Positive results from this study will make a strong case for trialling the drugs in people with KCNT1-epilepsy, with children suffering from this severe form of epilepsy having immediate access to successful drugs.

Image credit: 漏stock.adobe.com/au/Kateryna_Kon